Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo

Abstract

J2E cells produce rapid, fatal erythroleukemias in vivo but still respond to erythropoietin (epo) in vitro by differentiating, proliferating and remaining viable in the absence of serum. Mutant epo receptors were introduced into these cells to determine whether they could influence the different biological responses to epo in vitro and the development of erythroleukemias. Three mutant receptors were used as cytoplasmic truncation mutants Δ257 and Δ321 (above box 1 and below box 2 respectively), and the cytoplasmic point mutant W282R (defective for JAK2 activation). Strikingly, the Δ321 mutation produced a hyper-sensitive response in vitro to epo-induced differentiation and viability, but not to proliferation. In contrast with the Δ321 receptor, the Δ257 and W282R mutants inhibited all biological responses to epo due to impaired JAK2 phosphorylation. Significantly, erythroleukemias took almost twice as long to develop with cells containing the W282R mutation, indicating that JAK2 plays an important role in the emergence of these leukemias. These data demonstrate that mutant epo receptors dominantly altered responses of J2E cells to epo in culture and the development of erythroleukemias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Arcasoy MO, Degar BA, Harris KW and Forget GB. . 1997 Blood 89: 4628–4635.

  • Arcasoy MO, Harris KW and Forget GB. . 1999 Exp. Haematol. 27: 63–74.

  • Barber DL, Corless CN, Xia K, Roberts TM and D'Andrea AD. . 1997 Blood 89: 55–64.

  • Barber DL, DeMartino JC, Showers MD and D'Andrea AD. . 1994 Mol. Cell. Biol. 14: 2257–2265.

  • Bennett JM, Catovsky D, Daniel M, Flandrin G, Galton D, Gradnick H and Sultan C. . 1976 Br. J. Hematol. 33: 451–458.

  • Bittorf T, Jaster R and Brock J. . 1994 Cell Signal 6: 305–311.

  • Busfield SJ and Klinken SP. . 1992 Blood 80: 412–419.

  • Busfield SJ, Farr TJ, Singh T, Sainsbury AJ and Klinken SP. . 1993a Growth Factors 9: 307–315.

  • Busfield SJ, Meyer GT and Klinken SP. . 1993b Growth Factors 9: 317–328.

  • Carroll MP, Spivak JL, McMahon M, Weich N, Rapp UR and May WS. . 1991 J. Biol. Chem. 266: 14964–14969.

  • Chappell D, Tilbrook PA, Bittorf T, Colley SM, Meyer GT and Klinken SP. . 1997 Cell Death Differ. 4: 105–113.

  • Chretien S, Moreau-Gachelin F, Apiou F, Courtois G, Mayeux P, Dutrillaux B, Cartron JP, Gisselbrecht S and Lacombe C. . 1994 Blood 83: 1813–1821.

  • Chretien S, Varlet P, Verdier F, Gobert C, Cartron J-P, Gisselbrecht S, Mayeux P and Lacombe C. . 1996 EMBO J. 15: 4174–4181.

  • Cooper MC, Levy J, Cantor LN, Marks PA and Rifkind RA. . 1974 Proc. Natl. Acad. Sci. USA 71: 1677–1680.

  • Cutler RL, Liu L, Damen JL and Krystal G. . 1993 J. Biol. Chem. 268: 21463–21465.

  • D'Andrea AD, Lodish HF and Wong GG. . 1989 Cell 57: 277–285.

  • D'Andrea AD, Yoshimura A, Yousoufian H, Zon LI, Koo J-W and Lodish HF. . 1991 Mol. Cell. Biol. 11: 1980–1987.

  • Damen JE, Cutler RL, Huaiyuan J, Yi T and Krystal G. . 1995b J. Biol. Chem. 270: 23402–23408.

  • Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL and Krystal G. . 1995a EMBO J. 14: 5557–5568.

  • de la Chapelle A, Traskelin A-L and Juvonen E. . 1993 Proc. Natl. Acad. Sci. USA 90: 4495–4499.

  • Farr TJ, Lai CM, Beilharz MW, Papadimitriou J, Riches K, Rossi E, Garcia-Webb P and Klinken SP. . 1995 Leukemia 9: 900–907.

  • Furukawa T, Narita M, Sakaue M, Otsuka T, Kuroha T, Masuko M, Azegami T, Kishi K, Takahashi M, Utsumi J, Koike T and Aizawa Y. . 1997 Br. J. Haem. 99: 222–227.

  • Gobert S, Chretien S, Gouileux F, Muller O, Pallard C, Dusanter-Fourt I, Groner B, Lacombe C, Gisselbrecht S and Mayeux P. . 1996 EMBO J. 15: 2434–2441.

  • Gobert S, Duprez V, Lacombe C, Gisselbrecht S and Mayeux P. . 1995 Eur. J. Biochem. 234: 75–83.

  • Gough N. . 1988 Anal. Biochem. 173: 93–95.

  • Hawley RG, Lieu FHL, Fong AZC and Hawley TS. . 1994 Gene Therapy 1: 136–138.

  • He T-C, Jiang N, Zhuang H and Wojchowski DM. . 1995 J. Biol. Chem. 270: 11055–11061.

  • Hilton DJ, Watowich SS, Katz L and Lodish HF. . 1996 J. Biol. Chem. 271: 4699–4708.

  • Hilton DJ, Watowich SS, Murray PJ and Lodish HF. . 1995 Proc. Natl. Acad. Sci. USA 92: 190–194.

  • Jelkmann W. . 1992 Physiol. Rev. 72: 449–489.

  • Johannsen H, Gross AJ and Jelkmann W. . 1989 Erythropoietin. Springer Verlag: Berlin pp. 80–91.

    Book  Google Scholar 

  • Klingmuller U, Bergelson S, Hsiao JG and Lodish HF. . 1996 Proc. Natl. Acad. Sci. USA 93: 8324–8328.

  • Klingmuller U, Lorenz U, Cantley LC, Neel BG and Lodish HF. . 1995 Cell 80: 729–738.

  • Klingmuller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC and Lodish HF. . 1997 Proc. Natl. Acad. Sci. USA 94: 3016–3021.

  • Klinken SP and Nicola NA. . 1990 Leukemia 4: 24–28.

  • Klinken SP, Nicola NA and Johnson GR. . 1988 Proc. Natl. Acad. Sci. USA 85: 8506–8510.

  • Koury MJ and Bondurant MC. . 1992 Eur. J. Biochem. 210: 649–663.

  • Kralovics R, Indrak K, Stopka T, Berman B, Prchal J and Prchal J. . 1997 Blood 90: 2057–2061.

  • Krantz SB. . 1991 Blood 77: 419–434.

  • Kuramochi S, Ikawa Y and Todokoro K. . 1990 J. Mol. Biol. 216: 567–575.

  • Lacronique V, Boureux A, Della Valle V, Poirel H, Tran Quang C, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J and Bernard O. . 1997 Science 278: 1309–1312.

  • Lai CM, Swaminathan N, Beilharz MW, Papdimitriou J and Klinken SP. . 1995 J. Interferon Cytokine Res. 15: 669–675.

  • Le Couedic JP, Mitjavila MT, Villeval JL, Feger F, Gobert S, Mayeux P, Casadevall N and Vainchenker W. . 1996 Blood 87: 1502–1511.

  • Li J-P, D'Andrea AD, Lodish HF and Baltimore D. . 1990 Nature 343: 762–764.

  • Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK and Wilson IA. . 1996 Science 23: 464–471.

  • Longmore GD and Lodish HF. . 1991 Cell 67: 1089–1102.

  • Matthews DJ, Topping RS, Cass RT and Giebel LB. . 1996 Proc. Natl. Acad. Sci. USA 93: 9471–9486.

  • Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A and Roifman CM. . 1996 Nature 379: 645–648.

  • Mitjavila MT, Le Couedic JP, Casadevall N, Navarro S, Villeval JL, Dubart A and Vainchenker W. . 1991 J. Clin. Invest. 88: 789–797.

  • Miura O, Cleveland JL and Ihle JN. . 1993 Mol. Cell. Biol. 13: 1788–1795.

  • Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN and Aoki N. . 1994a Blood 84: 1501–1507.

  • Miura Y, Miura O, Ihle JN and Aoki N. . 1994b J. Biol. Chem. 269: 29962–29969.

  • Nakamura Y and Nakauchi H. . 1994 Science 264: 588–589.

  • Peeters P, Raynaud S, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H and Marynen P. . 1997 Blood 90: 2535–2540.

  • Penta K and Sawyer ST. . 1995 J. Biol. Chem. 270: 31282–31287.

  • Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravapodis D, Weinstein Y and Ihle JN. . 1996 Mol. Cell. Biol. 16: 1622–1631.

  • Ruscetti SK, Janesch NJ, Chakraborti A, Sawyer ST and Hankins WD. . 1990 J. Virol. 64: 1057–1062.

  • Sharlow ER, Pacifici R, Crouse J, Batac J, Tododkoro K and Wojchowski D. . 1997 Blood 90: 2175–2187.

  • Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL and Prchal JT. . 1995 Blood 86: 15–22.

  • Tauchi T, Damen JE, Toyama K, Feng G-S, Broxmeyer HE and Krystal G. . 1996 Blood 87: 4495–4501.

  • Tauchi T, Feng G-S, Shen R, Hoatlin M, Bagby GC, Kabat D, Lu L and Broxmeyer HE. . 1995 J. Biol. Chem. 270: 5631–5635.

  • Tilbrook PA, Bittorf T, Busfield SJ, Chappell D and Klinken SP. . 1996a J. Biol. Chem. 271: 3453–3459.

  • Tilbrook PA, Bittorf T, Callus B, Busfield SJ, Ingley E and Klinken SP. . 1996b Cell Growth Differ. 7: 511–520.

  • Tilbrook PA, Ingley E, Williams JH, Hibbs ML and Klinken SP. . 1997 EMBO J. 16: 1610–1619.

  • Torti M, Marti KB, Altschuler D, Yamamoto K and Lapetina EG. . 1992 J. Biol. Chem. 267: 8293–8298.

  • Watowich SS, Hilton DJ and Lodish HF. . 1994 Mol. Cell. Biol. 14: 3535–3549.

  • Watowich SS, Liu KD, Xie XL, Mikami A, Longmore GD and Goldsmith MA. . 1999 J. Biol. Chem. 274: 5415–5421.

  • Watowich SS, Yoshimura A, Longmore GD, Hilton DJ, Yoshimura Y and Lodish HF. . 1992 Proc. Natl. Acad. Sci. USA 89: 2140–2144.

  • Winkelman JC, Ward J, Mayeux P, Lacombe C, Schimmenti L and Jenkins RB. . 1995 Blood 85: 179–185.

  • Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O and Ihle JN. . 1993 Cell 74: 227–236.

  • Yi T, Zhang J, Muira O and Ihle JN. . 1995 Blood 85: 87–95.

  • Yoshimura A, D'Andrea AD and Lodish HF. . 1990a Proc. Natl. Acad. Sci. USA 87: 4139–4143.

  • Yoshimura A, Longmore G and Lodish HF. . 1990b Nature 348: 647–649.

  • Zhuang H, Niu Z, He T-C, Patel SV and Wojchowski DM. . 1995 J. Biol. Chem. 270: 14500–14504.

Download references

Acknowledgements

Recombinant human epo (Eprex) was a generous gift from Dr J Adams and Dr J Patava (Janssen-Cilag, Australia). We thank Shane Meakins, Jennifer Beaumont and Ruth Busche for excellent technical assistance. This work was supported by grants from NHMRC (99-0596) and Cancer Foundation of Western Australia (to PA Tilbrook) and grant-in-aid (96G-01616) from the American Heart Association, Texas Affiliate, Inc, Texas Higher Education Co-ordinating Board (ARP 15-120) (to SS Watowich).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cull, V., Tilbrook, P., Adenan, A. et al. Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo. Oncogene 19, 953–960 (2000). https://doi.org/10.1038/sj.onc.1203370

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203370

Keywords

This article is cited by

Search

Quick links